Ken Skidmore Email and Phone Number

Responsible for creating access, and coverage with commercial payers, Medicare and Medicaid and supporting hospital utilization for Iovance's autologous cellular tumor infiltrating lymphocyte (TIL) therapy.

Responsible for appropriate access of Kite Pharma’s novel CAR T immunotherapy YESCARTA with commercial, Medicare and Medicaid payersEducate Academic Centers of Excellence on coverage, coding and payment around first-in-class novel hematology/oncology biologicMinimize barriers to access while aiding in the launch of Kite Pharma from its clinical stage to commercial readiness.

Promoted based on achievements improving access and coverage with commercial, Medicare, and Medicaid payers for Soliris and launched Strensiq (pharmacy benefit) and Kanuma (medical benefit) achieving access to label. Accountable for inpatient and outpatient hospital access to treatment and work with the Complement and Metabolics Sales Teams in CT, MA, ME, NH, NJ, NY, PA, RI and VT. Collaborate with OneSource Case Managers to support customers with complex claims denials and appeals. Key accounts include Highmark, Excellus, Emblem NY, BCBS of RI / VT / MA, Harvard Pilgrim, Tufts, Capitol BCBS, and HealthNow. Previous accounts included United Healthcare, Aetna, and Cigna. Key Achievements:♦ Co-led a National Government Services Medicare Area Contractor JK (CT, MA, ME,NH, NY, RI, VT) and J-6 (MN,IL, MN) Cross Functional Team that stopped a restrictive Soliris local coverage decision (LCD) for paroxysmal nocturnal hemoglobinuria (PNH) from going into effect in 2015. o Raised awareness of physicians and patient advocacy groups to advocate for modifications to NGS on restrictive criteria. ♦ Protected 23% of Alexion’s PNH Medicare Sales due to successful implementation of education and advocacy strategies which blocked the NGS LCD.♦ Improved access to treatment with Soliris for existing and future patients with PNH and aHUS with Anthem by achieving 5 important modifications to the Anthem Soliris Medical Policy. ♦ Improved hospital in-patient access to Soliris by demonstrating cost savings from reduced in-patient hospital stays and better outcomes for patients with atypical hemolytic uremic syndrome (aHUS). ♦ Led cross functional United Healthcare Team that developed new Soliris Medical Policy, which allows aHUS and PNH patient access to treatment with the largest commercial insurer in the United States.

Recruited to improve market access for Soliris with commercial and government payers as a member of the Commercial Senior Leadership Team. Managed the $180,000 market access budget. Collaborated with 2 Directors of Sales (North and South), 60 sales people, 15 OneSource Case Managers and the PNH, and aHUS Marketing Teams. Key Achievements:♦ Achieved removal of the complement level criteria for aHUS in the Cigna Soliris Medical Policy in December 2014 by collaborating with Alexion CCO, aHUS Marketing Team and Global Medical Affairs, reviewing clinical literature supporting removal of the requirement, and developing an aHUS and Soliris Clinical Update Slide presentation for utilization with Cigna Senior Medical Director's personnel. ♦ Integral in development and approval of an aHUS Pathway at the University of Cinn in 2015, which led to identification and treatment of new patients with Soliris in the hospital setting at UCMC. o Collaborated with colleagues to develop a business plan to meet with key hematologists, transplant nephrologist, pharmacy director and clinical pharmacists at UCinn to increase confidence in diagnosing aHUS, and improve hospital in-patient access to Soliris.♦ Removed barriers for inpatient hospital access to Soliris by educating pharmacy directors and physicians on the cost effectiveness and improved outcomes of treating aHUS with Soliris at Hackensack Medical Center, Henry Ford Hospital, Beth Israel Deaconess, Yale New Haven Hospital, Massachusetts General Hospital, and Columbia Medical Center. ♦ Achieved publication of a new Soliris Medical Policy at Capital BCBS removing the plasma criteria and reducing the PNH red blood cell transfusion requirements from 4 in 12 months to 1 in 24 months.

Worked with physicians, office staff, case managers and sales teams to resolve claims denials and developed plan of action for appeals. Partnered with field sales and internal customers to explain public and private payer policies and processes impacting patient access to Genentech products with MD offices in NY, NJ, CT RI, MA, VT ME and NH. Key Achievements: ♦ Assisted physicians, and office staff to help support claims during appeals, and reduce initial claims denials due to continuing reimbursement and billing education.

Promoted to launch Boniva in the highly competitive osteoporosis market, and secure positive formulary access and grow market share for product portfolio with managed care accounts in CT, RI, and NY. Key accounts included Oxford Health Plan (CT, NY), Connecticare, HealthNet, BCBS RI and CDPHP. Collaborated with Brand Management, Legal, Regulatory, Compliance, Sales Directors, and National Account Managers on pull-through / push-through initiatives for existing products / new products, and implementation of programs at the field level. Key Achievements:♦ Increased market share for Nutropin 39 points to an 89% market share by developing a business proposal in collaboration with PBM colleague to offer an enhanced rebates through Caremark. ♦ Presented new program to Genetech Pricing and Contracting Committee and gained approval for the new preferred, Tier II Nutropin Caremark Rebate Contract. Partnered with NAMs and field sales to pull through messaging strategies / activities.♦ Developed B2B relationships with Pharmacy Directors at Oxford Health Plan and conducted speaker programs attended by case managers to provide clinical education to maintain unrestricted access to Avastin, Herceptin, Rituxan, Pegasys and Cellcept to commercial managed care plans which resulted in unrestricted access to treatment. ♦ Conducted disease state and product clinical updates for oncology (Xeloda) and HCV (Pegasys) products to key pharmacy directors and clinical pharmacists to differentiate products in an increasingly competitive pharmaceutical marketplace.♦ Provided input on a managed care sales tracking program for regional and national managed care plans, which detailed sales and market share for Roche products.♦ Recognized as United and Caremark Regional Account Manager of the Year (2010) and earned Special Achievement Awards (2008, 2009) for Boniva Managed Care Formulary Achievement.♦ Honored with a HIRC Best Account Manager Disease State Management Award (2008).

Promoted and generated $12.2 million in sales and grew market share for Rochephin, Versed, Cellcept and Kytril by forming and maintaining B2B relationships with pharmacy directors, hospital administrators, and physicians at IDNs in MA, CT, RI, and NH. Led pull-through strategies for 7 sales team comprised of Division Managers and Sales Specialists. Key hospital system accounts, included Partners Health System, Yale New Haven, Dartmouth - Hitchcock, LifeSpan, Caritas, and Beth Israel. Key Achievements:♦ Outperformed annual sales goal by 129.9% by building strong B2B relationships with key decision makers and leading pull through sales teams, which resulted in ranking #2 in the nation for goal attainment.

Led, managed, hired and developed 9 oncology sales specialists generating $40 million in sales for Roche oncology products in NY, NJ, and CT. Allocated a $270,000 promotional and travel / expense budget. Trained sales representatives on selling skills and clinical product knowledge for infused and oral oncology products.Key Achievements:♦ Ranked #1 division in the nation for Kytril market share (2001, 2002) while leading district through 3 sales expansions.

•Xeloda CRC National Launch Meeting Coordinator: created meeting agenda, sales training binder and sales training workshops•Created, conducted, and implemented a comprehensive sales training curriculum for breast cancer, colorectal cancer and hematology products (Xeloda, Roferon-A & Vesanoid)•Trained new sales representatives on product/market knowledge and sales skills for Xenical, Rocephin, Versed, Nolvadex, Cytovene, Fortovase, and Coreg

•Educated private and hospital physicians and staff on the features and benefits of Roche's products•Special Achievement Award for sales performance 1997

•Coordinated police, fire, and housing code enforcement in the Edgewood neighborhood

•Professional high merit and sales performance 1994 (6th out of 85 representatives)•Regional Rookie of the Year for sales achievement 1992